Thrombolytic Science, LLC (TSI) is a private, clinical stage biopharmaceutical company that was founded in 2006 based on the research of Harvard scientist Victor Gurewich into the potential use of prourokinase to break up blood clots. Gurewich co-founded the company and the founding CEO is business person Alexis Wallace. TSI's lead drug candidate is a synergistic sequential dual therapy combination of mutant prourokinase (the precursor form of urokinase) and a small dose of tPA [Tissue Plasminogen Activator]. TSI is developing its dual therapy as a potential treatment for conditions caused by blood clots, initially for ischemic stroke and heart attacks. More information...
According to PR-model, tsillc.net is ranked 2,376,948th in multilingual Wikipedia, in particular this website is ranked 1,304,203rd in English Wikipedia.
The website is placed before pravidhik.com and after constructionsphere.com in the BestRef global ranking of the most important sources of Wikipedia.
